triple-negative-breast-cancer

Documents about triple-negative-breast-cancer

• AMTEC IIT: Phase 2 Multiarm Study in TNBC#863800ClinicalTrials.gov
• Computational Design of an mRNA Vaccine Targeting LRP6 for Triple-Negative Breast Cancer Therapy.#159740NCBI PubMed Central
• Spatially distinct chromatin compaction states predict neoadjuvant chemotherapy resistance in Triple Negative Breast Cancer#367236Europe PMC
• Decoding triple negative breast cancer bone metastasis: from 3D bioprinted models to clinical translation.#645611NCBI PubMed Central
• Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC#876271ClinicalTrials.gov
• Phase II ABT-888 With Cyclophosphamide#801943ClinicalTrials.gov
• Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer#307441ClinicalTrials.gov
• Labdane diterpenoids from Leonotis ocymifolia with selective cytotoxic activity against HCC70 breast cancer cell line#626978University of Pretoria Repository
• Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients#890789ClinicalTrials.gov
• An ERRα-ZEB1 transcriptional signature predicts survival in triple-negative breast cancers#442573HAL (France)
• A Phase 1 Study of [225Ac]-FPI-1434 Injection#859603ClinicalTrials.gov
• A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer#245489ClinicalTrials.gov
• Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors#181763ClinicalTrials.gov
• A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations#1046551ClinicalTrials.gov
• Phase II Study of Combined Modality Treatment in Patients With Triple Negative Breast Cancer (TN-BC)#308462IRIS
• The YAP-TEAD4 inhibitor M511-0965 suppresses triple-negative breast cancer progression by downregulating TGFB2.#334998NCBI PubMed Central
• Machine learning-based prognostic model for triple-negative breast cancer with axillary lymph node metastasis.#402612NCBI PubMed Central
• Transcriptomic Association of COL3A1(+) Fibroblasts With Mechanical Pain-Related Gene Signatures in Triple-Negative Breast Cancer.#427642NCBI PubMed Central
• Metabolic-Immune Reprogramming via CuZnS@BSA Nanoregulators to Overcome Resistance in Triple-Negative Breast Cancer.#433972NCBI PubMed Central
• The VEGF/VEGFR axis in triple-negative breast cancer: a comprehensive review of therapeutic strategies#440218AVESIS
• A glucose metabolism-targeted nanoplatform amplifies disulfidptosis-associated immunogenic cell death in triple-negative breast cancer.#659640NCBI PubMed Central
• Human brain pericytes protect the blood–brain barrier from triple‐negative breast cancer cells while promoting tumor aggressiveness#156244HAL (France)
• Performance of MRI-based deep learning models in differentiation of triple negative breast cancer from other breast cancer subtypes: A systematic review and meta-analysis.#663319PubMed
• Tumour cell-intrinsic complement C1r and C1s regulate cancer cell fitness and shape the immune microenvironment in triple-negative breast cancer#156108HAL (France)
• Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells#1008233ClinicalTrials.gov
• Development of predictive models for the prognosis of triple-negative breast cancer using multiple transcriptomic analyses.#154530NCBI PubMed Central
• Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC#160370ClinicalTrials.gov
• Data Management and Sharing Plan for: Sentinel Lymph Node Immune Signatures and Association with Outcome in Triple Negative Breast Cancer#207868UNC Dataverse Dataverse OAI Archive
• Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC#256900ClinicalTrials.gov
• Development and verification of a prognostic nomogram model for triple-negative breast cancer patients with neoadjuvant therapy.#275626NCBI PubMed Central
• Body Size, Physical Activity, and Risk of Triple-Negative and Estrogen Receptor–Positive Breast Cancer#384047CiNii
• A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer#435753ClinicalTrials.gov
• Risk stratification and multi-omics reveal RAD51 inhibition as a radiosensitizing strategy in triple-negative breast cancer.#449937NCBI PubMed Central
• AS1411-functionalized albumin nanoparticles for nucleolin-targeted realgar delivery and therapy in triple-negative breast cancer.#452941NCBI PubMed Central
• Diagnostic delays, treatment timeliness, and patient experiences in triple-negative breast cancer: a mixed-methods study.#469042NCBI PubMed Central
• A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC#800770ClinicalTrials.gov
• PhI to Solid Tumors and PhII to Locally Advanced or mTNBC#861144ClinicalTrials.gov
• The tumor microenvironment in triple negative breast cancer and a strategy to improve responses to immunotherapy using cryoablation and immunostimulants#273474Europe PMC
• Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)#1031138ClinicalTrials.gov
• Role of genetic variations of parp1 polymorphisms on triple negative breast cancer (TNBC) susceptibility risk#279008USM Repository
• Antitumoral activities of λ‑carrageenan oligosaccharide- based nanoparticles#630249HAL (France)
• Supplementary Material for: Early-onset DAT-negative autoimmune hemolytic anemia induced by pembrolizumab in perioperative triple-negative breast cancer: a case report#291328Figshare
• Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)#872636ClinicalTrials.gov
• Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)#980809ClinicalTrials.gov
• ON-treatment Single-cell Analysis for the Identification of Early Tumor Response Biomarkers on Prospective Collected Serial Tumor Biopsies in Triple Negative Breast Cancer Patient During Standard Neoadjuvant Chemo-immunotherapy#363607ClinicalTrials.gov
• Nomograms for the prognosis prediction model of early-stage triple-negative breast cancer - based on SEER database.#13561NCBI PubMed Central
• Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy#14285HAL (France)
• Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy#180381ClinicalTrials.gov
• MnUA-DOX-artesunate hydrogel remodels immunosuppressive tumor microenvironment and prevents postoperative recurrence in triple-negative breast cancer.#242356NCBI PubMed Central
• Dual-Approach Characterization of Key Gene Markers in Triple-Negative Breast Cancer Through Comprehensive Bioinformatics and Machine Learning Integration#405972KFUPM ePrints